Aussie medtech to expand footprint of diagnostic technology for heart disease

MedTech & Diagnostics News: Heart disease is the leading cause of death in Australia. A Perth-based medical technology company has achieved a significant milestone by securing the first commercial agreement locally for its AI-driven heart disease-detection technology. This agreement paves the way for anticipated revenue to be recorded in the current quarter of the financial year.

Under the terms of the 12-month agreement, The Cardiac Centre and The Cardiac CT Centre NSW will utilise Artrya’s Salix Coronary Anatomy technology for detecting vulnerable plaque in patients, a crucial precursor to heart disease incidence.

The Salix platform is slated for implementation across four specialised centres within The Cardiac Centre NSW, located in Wollongong, Shellharbour, Bowral, and Nowra, collectively catering to over 25,000 patients annually for heart disease treatment. The AI-driven Salix platform will provide full diagnostic and evidence-based assessment within 10 minutes of first scan, dramatically improving the diagnosis workflow of coronary artery disease, saving unnecessary costs and minimising patient re-admissions.

Artrya CEO Mathew Regan expressed enthusiasm about the partnership, stating, “Artrya delivers what we believe is the most advanced and seamless technology platform on the market for the detection, diagnosis, and care of coronary artery disease, creating a new standard of care for the number one cause of death in the world.”

Dr Barry Elison, senior cardiovascular imaging specialist at The Cardiac CT Centre NSW, lauded the Artrya technology, highlighting its potential to enhance cardiac services for patients.

“This unique technology enables us to take a risk-based approach to patient care and personalised treatment by having a clear understanding of the different stages of plaque, and specifically the plaque that causes heart attacks,” remarked Dr Elison.

Moreover, Dr Jorge Moragues, a cardiologist and cardiac imaging specialist at The Cardiac CT Centre NSW, underscored the superiority of Artrya’s technology over existing methods of heart disease diagnosis.

“One of the limitations of current standard diagnostic methods of ischaemic heart disease is the reliance on symptoms, as up to 50% of individuals who experience a heart attack may not have had any previous long-term or overt symptoms,” said Dr Moragues. “Salix not only assists in identifying vulnerable plaque, an accurate indicator of disease, but significantly improves the diagnostic workflow of coronary artery disease.”

Looking ahead, Mr Regan sees the agreement with The Cardiac Centre NSW as a robust foundation for Artrya’s expansion plans within the state and nationally.

“Heart disease is the leading cause of death in Australia, killing 155 Australians each day,” highlighted Mr Regan. “Our AI-driven Salix Coronary Anatomy solution provides the first new approach to coronary heart diagnosis and care in 50 years; a game-changer in heart disease diagnosis, saving billions of unnecessary costs and minimising patient readmissions.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.